臺北醫學大學生醫器材研究中心

Pharmacology, Toxicology and Pharmaceutical Science

1. Malignant Neoplasm 100%
2. Nanoparticle 79%
3. Disease 54%
4. Neoplasm 52%
5. Chitosan 50%
6. Mouse 49%
7. Cohort Study 49%
8. Randomized Controlled Trial 44%
9. Chronic Kidney Failure 44%
10. Reactive Oxygen Metabolite 39%
11. Inflammation 37%
12. Chronic Obstructive Lung Disease 37%
13. Hyaluronic Acid 29%
14. Lung Cancer 29%
15. Hemodialysis 28%
16. Gelatin 28%
17. Fucoidan 28%
18. Vaccination Policy 27%
19. Sleep Disordered Breathing 27%
20. Epidermal Growth Factor Receptor 27%
21. Endothelin 1 26%
22. Cytotoxicity 25%
23. Doxorubicin 24%
24. Antioxidant 22%
25. Breast Cancer 22%
26. Combination Therapy 21%
27. Cell Viability 21%
28. Liposome 20%
29. Infection 19%
30. Diabetes Mellitus 18%
31. Antiinfective Agent 18%
32. Mitogen Activated Protein Kinase 18%
33. Cardiovascular Disease 18%
34. Symptom 17%
35. Adverse Event 17%
36. Chemotherapy 17%
37. Angiotensin II 17%
38. Lipopolysaccharide 17%
39. Bipolar Disorder 17%
40. Asthma 16%
41. Alginic Acid 16%
42. Injury 16%
43. Drug Delivery System 16%
44. Tumor Necrosis Factor 16%
45. Nitric Oxide 15%
46. Tumor Growth 15%
47. Growth Factor 15%
48. Calcium Phosphate 15%
49. Biocompatibility 15%
50. Therapeutic Effect 14%
51. Wound Healing 14%
52. Cytokine 14%
53. Rat Model 13%
54. Epigallocatechin Gallate 13%
55. Hydroxyapatite 13%
56. Nanocarrier 13%
57. Leporidae 13%
58. Prevalence 13%
59. Survival Rate 12%
60. Non Small Cell Lung Cancer 12%
61. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 12%
62. Atrial Fibrillation 12%
63. Case-Control Study 12%
64. End Stage Renal Disease 12%
65. Parkinson's Disease 12%
66. Heart Infarction 12%
67. Implant 11%
68. Fibrinogen 11%
69. Western Blot 11%
70. Infectious Agent 11%
71. Nanomaterial 11%
72. Lung Adenocarcinoma 11%
73. Liver Cell Carcinoma 11%
74. Alkaline Phosphatase 11%
75. Biological Marker 11%
76. Urotensin II 11%
77. Acute Heart Infarction 11%
78. Sleep Disorder 11%
79. Drug Release 11%
80. Polyglutamic Acid 10%
81. Mesoporous Silica Nanoparticle 10%
82. Nuclear Factor 10%
83. Cisplatin 10%
84. Receptor 10%
85. Thrombosis 10%
86. Clinical Trial 10%
87. Non Insulin Dependent Diabetes Mellitus 10%
88. Dry Eye 10%
89. Resveratrol 10%
90. Fibrosis 10%
91. Placebo 10%
92. Cyclooxygenase 2 10%
93. Colon Cancer 10%
94. All Cause Mortality 10%
95. Mouse Model 9%
96. Traumatic Brain Injury 9%
97. Spontaneously Hypertensive Rat 9%
98. Alternative Complement Pathway C3 C5 Convertase 9%
99. Side Effect 9%
100. Wound 9%

Medicine and Dentistry

1. In Vitro 66%
2. Meta-Analysis 53%
3. Implant 47%
4. Platelet 47%
5. Randomized Controlled Trial 46%
6. Cohort Analysis 42%
7. Malignant Neoplasm 38%
8. Apoplexy 36%
9. Systematic Review 36%
10. Platelet Lysate 35%
11. Chronic Kidney Disease 35%
12. Medicine 32%
13. Restylane 30%
14. Isotopes of Calcium 30%
15. Disease 30%
16. Chronic Obstructive Pulmonary Disease 29%
17. Hazard Ratio 24%
18. Diabetes Mellitus 23%
19. Symptom 23%
20. Fibroblast 23%
21. Neoplasm 22%
22. Influenza Vaccination 21%
23. Oral Implants 20%
24. Obstructive Sleep Apnea 19%
25. Rehabilitation Engineering 19%
26. Odds Ratio 19%
27. Injury 19%
28. Cancer Cell 18%
29. Osseointegration 18%
30. COVID-19 18%
31. Chondrocyte 17%
32. Lung Cancer 17%
33. Growth Factor 16%
34. Cell Therapy 16%
35. Hemodialysis 16%
36. Infection 16%
37. Health Care Cost 16%
38. Surgery 16%
39. Breast Cancer 16%
40. Osteolysis 15%
41. Mesenchymal Stem Cell 15%
42. Thrombocyte Concentrate 15%
43. Endothelial Cell 15%
44. Knee 15%
45. Programmed Cell Death 15%
46. Nanoparticle 15%
47. Spinal Cord Injury 14%
48. Bone Regeneration 14%
49. Blood Pressure 14%
50. Computer Assisted Tomography 14%
51. Drug Therapy 14%
52. Gelatin 14%
53. Epidermal Growth Factor Receptor 14%
54. Functional Electrical Stimulation 14%
55. Dental Implant 14%
56. Prevalence 13%
57. Hydroxylapatite 13%
58. Platelet-Rich Fibrin 13%
59. Ossification 13%
60. Cardiovascular System 13%
61. Biological Marker 13%
62. Cell Proliferation 12%
63. Bone Graft 12%
64. Gene Expression 12%
65. Adverse Event 12%
66. Electrostimulation 12%
67. Osteoblast 12%
68. Urination 12%
69. Signal Transduction 12%
70. Metastatic Carcinoma 12%
71. Acute Heart Infarction 12%
72. Quality of Life 12%
73. Cardiovascular Disease 11%
74. Tumor Progression 11%
75. Upper Limb 11%
76. Combination Therapy 11%
77. Knee Osteoarthritis 11%
78. Case-Control Study 11%
79. Clinical Trial 11%
80. Osteoarthritis 11%
81. Calcium Sulfate 11%
82. Traumatic Brain Injury 11%
83. Atrial Fibrillation 11%
84. Asthma 11%
85. Dental Pulp Stem Cell 10%
86. Bone Defect 10%
87. Diabetes 10%
88. Angiogenesis 10%
89. Heart Failure 10%
90. Tumor Necrosis Factor 10%
91. Magnetic Resonance Imaging 10%
92. Vascular Endothelial Cell 10%
93. Edentulism 10%
94. Parkinson's Disease 10%
95. Bone Substitutes 10%
96. Ischemia 10%
97. Diagnosis 10%
98. Pulse Rate 10%
99. Cell Viability 10%
100. 4 Iodo 2,5 Dimethoxyamphetamine 10%